ophthalmology
Gbola Amusa, Chardan Capital Markets head of healthcare research, commented in a note on Monday that investors should be "more selective" in the biotech space. As such, the analyst downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to Neutral from Buy with an unchanged $565 price... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to:
Gbola Amusa Wedbush David Nierengarten Mark Baum David Nierengarten Regeneron Pharmaceuticals Inc Spark Therapeutics Inc
Source: benzinga.com